地理因素对前列腺癌治疗选择的影响
基于美国国家医保数据库2011—2014年前列腺癌患者及美国医学会医师主文件,研究绘制了不同治疗模式提供者的地理分布图,并分析患者与提供者距离对治疗选择的影响。结果显示,传统治疗(IMRT、前列腺切除术、近距离放疗)提供者集中于大城市,农村地区尤其是近距离放疗提供者较少;新兴治疗(SBRT、质子治疗)提供者高度集中于城市。距离越远,接受治疗的概率越低。
要点
- 90%患者距前列腺切除术、IMRT、近距离放疗提供者分别在35.1、28.9、55.6英里内。
- 90%患者距SBRT和质子治疗提供者分别在128英里和374.5英里内。
- 距离每增加10英里,IMRT治疗概率降低3.8%,前列腺切除术降低2.1%,近距离放疗降低2%,质子治疗降低1.6%,SBRT降低1.1%。
核心结论
- 所分析的治疗模式存在地理差异,且这些差异影响治疗实施。
研究设计与样本
- 回顾性队列研究,患者队列来自国家医保数据库2011—2014年诊断并治疗的前列腺癌患者,提供者队列来自美国医学会医师主文件。
- 共纳入89,902例患者和5,518名医师。
- 使用多变量多项逻辑回归评估患者与提供者距离和治疗概率的关联。
主要发现
- 传统治疗(IMRT、前列腺切除术、近距离放疗)提供者在大城市中心数量多,农村地区减少,近距离放疗尤为明显。
- 新兴治疗(SBRT和质子治疗)提供者主要集中于城市。
- 90%患者距前列腺切除术、IMRT、近距离放疗提供者分别在35.1、28.9、55.6英里内;距SBRT和质子治疗提供者分别在128英里和374.5英里内。
- 距离增加与治疗概率降低相关:IMRT每10英里降低3.8%,前列腺切除术降低2.1%,近距离放疗降低2%,质子治疗降低1.6%,SBRT降低1.1%。
临床怎么用
- 临床转诊时应考虑患者居住地距不同治疗模式提供者的距离,可能影响治疗选择。
- 对于农村地区患者,近距离放疗等可及性较低的治疗模式需特别关注。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Several definitive treatment options are available for prostate cancer, but geographic access to those options is not uniform. We created maps illustrating provider practice patterns relation to patients and assessed the influence of distance to treatment receipt. METHODS AND MATERIALS: The patient cohort was created by searching the National Medicare Database for patients diagnosed and treated for prostate cancer from 2011 to 2014. The provider cohort was created by querying the American Medical Association Physician Masterfile to identify physicians who had treated patients with prostatectomy, intensity modulated radiation therapy (IMRT), brachytherapy, stereotactic body radiation therapy (SBRT), or proton therapy. Maps detailing the location of providers were created for each modality. Multivariate multinomial logistic regressions were used to assess the association between patient-provider distance and probability of treatment. RESULTS: Cohorts consisted of 89,902 patients treated by 5518 physicians. Substantial numbers of providers practicing established modalities (IMRT, prostatectomy, and brachytherapy) were noted in major urban centers, whereas provider numbers were reduced in rural areas, most notably for brachytherapy. Ninety percent of prostate cancer patients lived within 35.1, 28.9, and 55.6 miles of a practitioner of prostatectomy, IMRT, and brachytherapy, respectively. Practitioners of emerging modalities (SBRT and proton therapy) were predominantly concentrated in urban locations, with 90% of patients living within 128 miles (SBRT) and 374.5 miles (proton). Greater distance was associated with decreased probability of treatment (IMRT -3.8% per 10 miles; prostatectomy -2.1%; brachytherapy -2%; proton therapy -1.6%; and SBRT -1.1%). CONCLUSIONS: Geographic disparities were noted for analyzed treatment modalities, and these disparities influenced delivery.
引用
- Tang C, Lei X, Smith GL, et al. Influence of Geography on Prostate Cancer Treatment. Int J Radiat Oncol Biol Phys. 2020. PMID: 33316361. doi:10.1016/j.ijrobp.2020.11.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。